Vaccinex Stock Price, News & Analysis (NASDAQ:VCNX) $0.82 -0.04 (-5.00%) (As of 01:58 PM ET) Add Compare Share Share Today's Range$0.77▼$0.8750-Day Range$0.82▼$2.3952-Week Range$0.77▼$12.36Volume105,099 shsAverage Volume194,457 shsMarket Capitalization$10.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Vaccinex MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 2 Articles This WeekInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vaccinex. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.79% of the float of Vaccinex has been sold short.Short Interest Ratio / Days to CoverVaccinex has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccinex has recently increased by 32.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaccinex does not currently pay a dividend.Dividend GrowthVaccinex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCNX. Previous Next 3.3 News and Social Media Coverage News SentimentVaccinex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vaccinex this week, compared to 0 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,004,650.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders55.90% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccinex is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccinex is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaccinex has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaccinex Stock (NASDAQ:VCNX)Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More VCNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCNX Stock News HeadlinesNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSeptember 29, 2023 | finance.yahoo.comVaccinex Announces Pricing of $9.6 Million Public OfferingNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 28, 2023 | stockhouse.comVaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 28, 2023 | finance.yahoo.comVaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 27, 2023 | finance.yahoo.comVaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® ApplicationSeptember 26, 2023 | benzinga.comVaccinex Recent Insider ActivitySeptember 22, 2023 | marketwatch.comVaccinex Board to Implement 1-for-15 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comVaccinex, Inc. Announces Reverse Stock SplitAugust 14, 2023 | finance.yahoo.comVaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 1, 2023 | finance.yahoo.comVaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ETMay 31, 2023 | benzinga.comVaccinex Stock (NASDAQ:VCNX), DividendsMay 17, 2023 | seekingalpha.comVaccinex GAAP EPS of -$0.10, revenue of $0.55MMay 16, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 25, 2023 | finance.yahoo.comVaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of PepinemabApril 12, 2023 | finance.yahoo.comVaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian CellsApril 3, 2023 | finance.yahoo.comVaccinex Announces Private Placement with Commitments of $5.0 MillionApril 3, 2023 | finance.yahoo.comVaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical ProgramsMarch 23, 2023 | finance.yahoo.comVaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 21, 2023 | finance.yahoo.comVaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)March 9, 2023 | finance.yahoo.comVaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim AnalysisSee More Headlines Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.0376) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,820,000.00 Net MarginsN/A Pretax Margin-2,768.80% Return on Equity-2,667.31% Return on Assets-475.55% Debt Debt-to-Equity Ratio0.03 Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual Sales$280,000.00 Price / Sales37.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book0.54Miscellaneous Outstanding Shares12,490,000Free Float5,510,000Market Cap$10.62 million OptionableNot Optionable Beta1.14 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Maurice Zauderer Ph.D. (Age 77)Co-Founder, CEO, President & Director Comp: $400.7kDr. Elizabeth E. Evans Ph.D. (Age 51)COO and Senior VP of Discovery & Translational Medicine Comp: $255.46kDr. Ernest S. Smith Ph.D. (Age 51)Senior VP of Research & Chief Scientific Officer Comp: $284.02kMr. Scott E. Royer C.F.A. (Age 49)M.B.A., Chief Financial Officer Comp: $242.15kDr. John E. Leonard Ph.D. (Age 76)Senior Vice President of Development Key CompetitorsCNS PharmaceuticalsNASDAQ:CNSPFrequency TherapeuticsNASDAQ:FREQProMIS NeurosciencesNASDAQ:PMNAraviveNASDAQ:ARAVNightHawk BiosciencesNYSE:NHWKView All CompetitorsInsiders & InstitutionsWorth Venture Partners LLCBought 578,764 shares on 11/15/2023Ownership: 16.308%Armistice Capital LLCBought 680,000 shares on 11/15/2023Ownership: 15.455%AIGH Capital Management LLCSold 262,397 shares on 11/13/2023Ownership: 24.777%Albert FriedbergBought 3,000,000 shares on 10/3/2023Total: $3 M ($1.00/share)Maurice ZaudererBought 5,000 shares on 10/3/2023Total: $4,650.00 ($0.93/share)View All Insider TransactionsView All Institutional Transactions VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed in 2023? Vaccinex's stock was trading at $9.6675 at the beginning of 2023. Since then, VCNX shares have decreased by 91.5% and is now trading at $0.8201. View the best growth stocks for 2023 here. Are investors shorting Vaccinex? Vaccinex saw a increase in short interest in November. As of November 15th, there was short interest totaling 50,400 shares, an increase of 32.3% from the October 31st total of 38,100 shares. Based on an average daily volume of 631,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the company's shares are sold short. View Vaccinex's Short Interest. When is Vaccinex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our VCNX earnings forecast. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($2.55) earnings per share for the quarter, topping the consensus estimate of ($4.35) by $1.80. The firm had revenue of $0.05 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on Tuesday, September 26th 2023. The 1-15 reverse split was announced on Tuesday, September 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX). When did Vaccinex IPO? (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. Who are Vaccinex's major shareholders? Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (24.78%), Worth Venture Partners LLC (16.31%), Armistice Capital LLC (15.45%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van. View institutional ownership trends. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:VCNX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.